Semler Announces Investment in Monarch Medical Technologies – Yahoo Finance
SANTA CLARA, Calif., Dec. 12, 2022 /PRNewswire/ — Semler Scientific, Inc. (Nasdaq: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced an up to $5.0 million investment in privately-held Monarch Medical Technologies, LLC (Monarch) through the purchase of a senior secured convertible promissory note. Repayment of the note is secured by a first priority interest in all of Monarch’s assets.
Monarch is a digital health company whose proprietary EndoTool® Glucose Management System offers a technology-enabled approach to inpatient glycemic management. The software-as-a-service solution is FDA 510(k) cleared, patent protected and installed at more than 100 health systems across the United States.
The investment in Monarch complements Semler Scientific’s offering of Insulin Insights™, a glycemic management software application that healthcare providers can use to optimize outpatient insulin dosing for persons with diabetes.
“We are excited to add a second company in the diabetes management space to our network,” said Doug Murphy-Chutorian, M.D., chief executive officer of Semler Scientific. “We believe Monarch has a superior software solution to address customers’ concerns about nursing shortages and new CMS quality measures for hypoglycemia and hyperglycemia in the inpatient setting.”
About Semler Scientific, Inc.:
Semler Scientific, Inc. is a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers. Semler Scientific’s mission is to develop, manufacture and market innovative products and services that assist its customers in evaluating and treating chronic diseases. Semler Scientific’s patented and U.S. Food and Drug Administration (FDA) cleared product, QuantaFlo®, is a rapid point-of-care test that measures arterial blood flow in the extremities to aid in the diagnosis of cardiovascular diseases, such as peripheral arterial disease (PAD). QuantaFlo® is used by Semler Scientific’s customers to evaluate their patients more comprehensively for risk of mortality and major adverse cardiovascular events (MACE), associated with a positive QuantaFlo® test. Semler Scientific has an agreement with Mellitus Health to exclusively market and distribute Insulin Insights™, an FDA cleared software product that recommends optimal insulin dosing for diabetic patients in the United States, including Puerto Rico, except for selected accounts, and has made an investment in this private software company. Semler Scientific has also invested in privately held Monarch Medical Technologies, whose product, EndoTool®, is used for glycemic management in inpatient settings and in SynapsDX, whose product, Discern™, is a test for early Alzheimer’s disease. Semler Scientific continues to develop additional complementary innovative products in-house and seeks out other arrangements for additional products and services that it believes will bring value to its customers and to the company. Semler Scientific believes its current products and services, and any future products or services that it may offer, positions it to provide valuable information to its customer base, which in turn permits them to better guide patient care. Additional information about Semler Scientific can be found at www.semlerscientific.com.
About Monarch Medical Technologies, LLC:
Monarch Medical Technologies is a digital health company committed to helping hospitals and health systems deliver optimal glycemic management for critical care and non-critical care patients alike. The company’s FDA-cleared EndoTool® Glucose Management System is designed specifically to displace traditional manual methods of insulin dosing with an intuitive and easy-to-use software application that integrates seamlessly with all major EMR systems. This pioneering clinical decision support platform offers both intravenous and subcutaneous modalities and has been shown to safely and reliably achieve and maintain target glucose goals while reducing incidence of hyperglycemia and hypoglycemia. Specialized features help clinicians address the complexities surrounding diabetic ketoacidosis (DKA), hyperosmolar hyperglycemic nonketotic syndrome (HHS), gestational diabetes, kidney function, residual insulin, and presence of steroids. Additional information about Monarch can be found at www.monarchmedtech.com.
Forward-Looking Statements
This press release contains “forward-looking” statements. Such statements can be identified by, among other things, the use of forward-looking language such as the words “goal,” “may,” “will,” “intend,” “expect,” “anticipate,” “estimate,” “project,” “would,” “could” or words with similar meaning or the negatives of these terms or by the discussion of strategy or intentions. The forward-looking statements in this release include express or implied statements regarding Semler Scientific’s investment in Monarch and Monarch’s software and its ability to optimize outpatient insulin dosing, among others. Such forward-looking statements are subject to a number of risks and uncertainties that could cause such forward-looking statements to differ materially from those discussed herein, such as whether or not Semler Scientific will loan additional funds to Monarch, risks associated with investing in private companies, risks associated with Monarch’s software and whether or not Semler Scientific will be repaid or receive value for its investment in Monarch, , along with those risk factors affecting Semler Scientific’s business that are detailed in Semler Scientific’s filings with the Securities and Exchange Commission. These forward-looking statements involve assumptions, estimates, and uncertainties that reflect current internal projections, expectations or beliefs. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. All forward-looking statements contained in this press release are qualified in their entirety by these cautionary statements and the risk factors described above. Furthermore, all such statements are made as of the date of this release and Semler Scientific assumes no obligation to update or revise these statements unless otherwise required by law.
INVESTOR CONTACT:
Susan A. Noonan
S.A. Noonan Communications
susan@sanoonan.com
917 513 5303
View original content:https://www.prnewswire.com/news-releases/semler-announces-investment-in-monarch-medical-technologies-301699977.html
SOURCE Semler Scientific, Inc.
Related Quotes
A look at the shareholders of Lam Research Corporation ( NASDAQ:LRCX ) can tell us which group is most powerful. And…
The doom and gloom brigade has been out in full force recently, persistently warning the economy is in a precarious state and that a recession next year is all but inevitable. Maybe so, but that doesn't necessarily mean the stock market is destined to follow suit. In fact, the J.P. Morgan Asset Management team expects 2023 will be a “bad year for the economy, a better year for markets.” “Our core scenario sees developed economies falling into a mild recession in 2023,” added Asset Management tea
It's an announcement that is somewhat like a thunderbolt in the automotive industry. Three months ago, Rivian, which aims to challenge Tesla in the race for electric vehicles, announced with fanfare a partnership with Mercedes-Benz to manufacture electric vans in Europe. For Rivian , it was a key partnership as the company encountered difficulties in increasing its production capacities.
Brookfield Asset Management (NYSE: BAM) recently completed a unique stock split. Brookfield completed this split so that its investors would have direct exposure to its asset management business's dividend income and growth. CEO Bruce Flatt recently discussed the growth it has already locked up at a recent industry conference.
Is China's zero-Covid strategy finally over? While most Western nations have prioritized a return to normal and an end to COVID pandemic restrictions, China was the standout for maintaining its strongly restrictive lockdown policies. But there is mounting evidence that Beijing is looking for a way to back off from the lockdowns – and Chinese policymakers appear to be edging toward reopening their economy. That’s good news for investors, as a pullback from the zero-COVID controls in such major ci
In this article, we will take a look at the 10 cheap small-cap stocks to buy before the next breakout. If you want to see more stocks in this selection, go to the 5 Cheap Small-Cap Stocks to Buy Before the Next Breakout. Some of the prominent large and mega-cap stocks in the world today used […]
Investors who bought the dip in Cathie Wood ‘s ARK Innovation exchange-traded fund have been punished this year. Shares of the fund, a pandemic-era favorite largely made up of unprofitable, growth-oriented technology companies, are down 63% this year. Investors have bailed out of growth stocks and other speculative assets en masse this year.
Investment banks see inflation falling in November, but that may not be enough to protect the U.S. economy from a recession.
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Intel Corporation (INTC) and Advanced Micro Devices, Inc. (AMD).
As FTX continues to be unwound, its new CEO is set to tell Congress at least five things he knows the company did with the money from clients and investors.
GE HealthCare management is meeting with investors before it separates from General Electric in early January.
Binance endured $902 million of net outflows in the past 24 hours, according to data by Nansen.
(Bloomberg) — With equity investors defensively positioned, a soft reading in Tuesday’s consumer price index could spark a powerful rally — with the S&P 500 jumping as much as 10%. That’s the bold forecast from JPMorgan Chase & Co.’s sales and trading desk. Most Read from BloombergElon Musk Is Ruining Trump’s Presidential CampaignChina’s Rapid Covid Reversal Sparks Whiplash as Cases SurgeSam Bankman-Fried Arrested in Bahamas as US Files FTX ChargesUS Says Scientists Make Breakthrough in Nuclear
Tesla Inc. stock on Monday ended at a fresh two-year low, going against broader market strength and as December losses look poised to match November's and October's double-digit declines.
When income investors purchase a real estate investment trust (REIT), one of the things they hope is that the stock will perform well enough for the company to increase its quarterly dividend as the years go by, raising the investor’s annual yield. Usually, the dividend hikes are 3 to 5 cents per year, and investors are happy if they can get that on a steady basis. For example, a $1 dividend on a $25 stock that increases its dividend by 5 cents per year can turn a 4% yield into a 5% yield in abo
Nvidia stock has rallied more than 50% from its October low. As it runs into the 200-day moving average, here's how to trade it now.
Petrobras (PBR) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
ExxonMobil (NYSE: XOM) shares closed out last week on a down note, as investors digested the details of the oil giant's latest "five-year plan": paying down debt, buying back stock, and allowing profits and cash flow to fall well below 2022 levels. You can thank the oil market for that. Oil prices popped Monday morning, with the cost of a barrel of WTI crude up 3.4% at $73.40 and Brent crude, the international benchmark, rising 2.8% to $78.19.
Recession is likely next year, at least according to the bond market. But some S&P 500 companies will skate right through it, analysts say.
Yahoo Finance Live anchors discuss the rise in stock for Coupa following Thoma Bravo’s $8 billion acquisition.